Skip to main
SXTP
SXTP logo

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc demonstrated significant growth with revenues reaching $310,000, reflecting a 20% sequential increase and an impressive 145% year-over-year rise. This robust revenue performance suggests a positive trajectory in the firm's commercial activities, particularly in its quest to develop therapies targeting infectious diseases. Additionally, the anticipated reduction in R&D expenses coupled with a higher share count supports an upward revision of the FY25 earnings per share estimate, further indicating a favorable outlook for the company's financial health.

Bears say

60 Degrees Pharmaceuticals Inc is facing a negative outlook primarily due to a significant reduction in forecasted revenue, attributed to low visibility regarding the company's capacity to ramp up sales. The firm reported a decline in product revenues to $100,000, primarily due to supply constraints, although this was somewhat mitigated by Australian research grant revenues. Additionally, uncertainties surrounding regulatory approvals for new product indications and the potential for dilution from future financing present substantial risks to the company's financial stability.

SXTP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 1 analysts, SXTP has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.